Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
1(50.0%)
Phase 3
1(50.0%)
2Total
N/A(1)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT05270278Completed

Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy

Role: lead

NCT05005052Phase 3Unknown

Sulodexide in the Treatment of Chronic Primary Venous Disease of the Lower Extremities

Role: lead

NCT05380843Unknown

Description of Treatment Patterns and Population Characteristics of Pre-dialysis CKD Patients in the Czech Republic

Role: lead

NCT04167423Completed

Mapping Health-related Quality of Life in Pregnant Women With Thyroid Disease.

Role: lead

NCT04171947Not ApplicableCompleted

Vaginal Ovule With Flavonoid Tea Extract for the Correction of Imbalance in the Vaginal Environment

Role: lead

All 5 trials loaded